Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ruxolitinib Monotherapy in Hydroxyurea or Interferon-α Resistant/Intolerant Polycythemia Vera
ChiCTR2100045795Phase 2Recruiting
- Sponsor
- Institute of Hematology and Blood Diseases Hospital
- Start
- Apr 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ruxolitinib in polycythemia vera (PV), sponsored by Institute of Hematology and Blood Diseases Hospital. Primary endpoint: Complete hematological response. Started Apr 2020; status: recruiting.
02
Drugs
03
Conditions
polycythemia vera (PV)
Beyond the preview
Go deeper on ChiCTR2100045795.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100045795.